Meeting
2022 ASCO Annual Meeting
Microsatellite-stable tumors with high tumor mutational burden in association with tumor response to immune checkpoint inhibitor therapy across solid tumors and correlation with specific oncogenic alterations.
Authors
Imran Nizamuddin
Northwestern University Feinberg School of Medicine, Chicago, IL
Imran Nizamuddin , Peter Doukas , Pedro Antonio Hermida de Viveiros , Xinlei Mi , Neelima Katam , Young Kwang Chae , Amir Behdad , Firas Hazem Wehbe , Devalingam Mahalingam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2634)
DOI
10.1200/JCO.2022.40.16_suppl.2634
Abstract #
2634
Poster Bd #
289
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Comprehensive whole genome and transcriptome analysis of patients with advanced solid tumor treated with immune checkpoint inhibitor therapy in the pan-cancer cohorts from the Marathon of Hope Cancer Centres Network Study (MOHCCN).
First Author: Khadjah Alshankati
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2022 ASCO Annual Meeting
Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development.
First Author: Dazhi Liu
Poster
2024 ASCO Genitourinary Cancers Symposium
Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: Nikhil Pramod